The weekly
One short email a week. New trials, rule changes, and what we got wrong.
Before you sign up
- We keep your email only to send the weekly. It is never shown and never sold.
- The first email asks you to confirm. If you don't, you get nothing more.
- Every email has a one-tap way to stop.
- Emails start soon. Until then, every issue is posted on this page.
- For adults. Information only. We never tell you what to take.
Latest issue
Issue 1 · Nov 13, 2026
What changed lately
Peptide pharmacy rules loosened, for now. In late October the US health department said it will not go after licensed pharmacies and doctors that make six peptides to order, including BPC-157. It is temporary. It is not an approval.
Retatrutide moved up to grade A. A final-stage trial in 2,339 adults was published on September 29, 2026. It is still not approved.
We got one wrong. We said Cardarine had no human results. A 12-week trial in 268 adults measured blood fats. Fixed.
Watching. Whether the pharmacy policy becomes permanent, and results from the JUMPFOOD collagen trial.
Keep going
We show what studies found. We never tell you what to take.